NEW YORK – Amgen's Xgeva, which is used to treat bone disorders related to cancer, received an additional U.S. marketing approval. The Food and Drug Administration approved Xgeva as a treatment for ...
"We now finally have evidence that bone-targeted treatment is not only successful in treating bony metastases and preventing treatment-induced bone loss," said Michael Gnant. A follow-up analysis of ...
Investor's Business Daily on MSN
Amgen tops buy zone on positive 2026 outlook amid sharpening obesity focus
Amgen is running a number of studies of its obesity drug, MariTide.
Amgen delivered a strong Q4 2025, exceeding revenue and EPS expectations and guiding for 2026 growth despite major loss of ...
Amgen wants to extend use of bone cancer drug Xgeva (denosumab) into the prevention setting, but analysts, not to mention the FDA’s own advisors, are not optimistic about its chances of securing the ...
Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the ...
Amgen today announced the FDA plans to decide by April 26 on its application to expand the use of its bone treatment drug Xgeva to prevent or delay the spread of advanced prostate cancer. The drug is ...
April 26 (Reuters) - U.S. health regulators rejected the application by Amgen Inc, the world's biggest biotechnology company, to expand the use of the drug Xgeva to delay the spread of tumors to the ...
THOUSAND OAKS, Calif., Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results